Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Allan Lipton, Harold Harvey, Bellarmine Lawrence, Robert Gottlieb, Miodrag Kukrika, Richard Dixon, William Graham, Stephen Miller, Robert Heckard, Dale Schelzel, Deborah S. White

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
JournalCancer
Volume51
Issue number1
DOIs
StatePublished - Jan 1 1983

Fingerprint

Propionibacterium acnes
Immunotherapy
Bacillus
Melanoma
Life Tables
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lipton, Allan ; Harvey, Harold ; Lawrence, Bellarmine ; Gottlieb, Robert ; Kukrika, Miodrag ; Dixon, Richard ; Graham, William ; Miller, Stephen ; Heckard, Robert ; Schelzel, Dale ; White, Deborah S. / Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. In: Cancer. 1983 ; Vol. 51, No. 1. pp. 57-60.
@article{5d4ccfab54c548af902dea239fceb5b9,
title = "Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma",
abstract = "One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.",
author = "Allan Lipton and Harold Harvey and Bellarmine Lawrence and Robert Gottlieb and Miodrag Kukrika and Richard Dixon and William Graham and Stephen Miller and Robert Heckard and Dale Schelzel and White, {Deborah S.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V",
language = "English (US)",
volume = "51",
pages = "57--60",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Lipton, A, Harvey, H, Lawrence, B, Gottlieb, R, Kukrika, M, Dixon, R, Graham, W, Miller, S, Heckard, R, Schelzel, D & White, DS 1983, 'Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma', Cancer, vol. 51, no. 1, pp. 57-60. https://doi.org/10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. / Lipton, Allan; Harvey, Harold; Lawrence, Bellarmine; Gottlieb, Robert; Kukrika, Miodrag; Dixon, Richard; Graham, William; Miller, Stephen; Heckard, Robert; Schelzel, Dale; White, Deborah S.

In: Cancer, Vol. 51, No. 1, 01.01.1983, p. 57-60.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

AU - Lipton, Allan

AU - Harvey, Harold

AU - Lawrence, Bellarmine

AU - Gottlieb, Robert

AU - Kukrika, Miodrag

AU - Dixon, Richard

AU - Graham, William

AU - Miller, Stephen

AU - Heckard, Robert

AU - Schelzel, Dale

AU - White, Deborah S.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

AB - One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

UR - http://www.scopus.com/inward/record.url?scp=0020659801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020659801&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

DO - 10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

M3 - Article

VL - 51

SP - 57

EP - 60

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -